First Analysis Initiates Coverage On LeMaitre Vascular Inc to Overweight with Price Target $29

First Analysis Initiates Coverage On LeMaitre Vascular Inc(LMAT). In a research note issued to the investors, the brokerage major Announces the price-target to $29 per share. The shares have been rated Overweight. The rating by the stock financial advisor at First Analysis was issued on Mar 21, 2017 in a research report to their Investors and Clients.

LeMaitre Vascular Inc (LMAT) shares turned negative on Fridays trading session with the shares closing down -0.16 points or -0.66% at a volume of 66,778. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $24.28. The peak price level was also seen at $24.28 while the days lowest was $22.954. Finally the shares closed at $23.95. The 52-week high of the shares is $27.0375 while the 52-week low is $13.06. According to the latest information available, the market cap of the company is $447 M.

LeMaitre Vascular Inc(LMAT) last announced its earnings results on Feb 21, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $23.288M. Analysts had an estimated revenue of $23.590M. Earnings per share were $0.13. Analysts had estimated an EPS of $0.15.

Several Insider Transactions has been reported to the SEC. On Mar 10, 2017, David B Roberts (President and Director) sold 5,900 shares at $22.44 per share price.Also, On Mar 1, 2017, George W Lemaitre (Chairman and CEO) sold 10,000 shares at $22.40 per share price.On Nov 18, 2016, Peter R Gebauer (President, International OP) sold 12,943 shares at $23.78 per share price, according to the Form-4 filing with the securities and exchange commission.

LeMaitre Vascular Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop manufacture and market medical devices and implants used primarily in the field of vascular surgery. The Company’s product lines include valvulotomes balloon catheters carotid shunts biologic patches biologic grafts radiopaque marking tape anastomotic clips remote endarterectomy devices laparoscopic cholecystectomy devices vascular grafts angioscopes and powered phlebectomy devices. The Company develops manufactures and markets vascular devices to address the needs of vascular surgeons. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart including the Expandable LeMaitre Valvulotome the Pruitt F3 Carotid Shunt VascuTape Radiopaque Tape and the XenoSure biologic patch.

Add Comment